Correlation Engine 2.0
Clear Search sequence regions

  • expert opinion (1)
  • free (1)
  • gene (1)
  • help (1)
  • humans (1)
  • patients (2)
  • t cell (2)
  • t cell lymphoma (6)
  • therapies (4)
  • therapies cell (1)
  • Sizes of these terms reflect their relevance to your search.

    Introduction: T-cell lymphomas represent a broad group of malignant T-cell neoplasms with marked molecular, clinical, and biologic heterogeneity. Survival rates after conventional chemotherapy regimens are poor for most subtypes and new therapies are needed. Rapidly expanding knowledge in the field of epigenomics and the development of an increasing number of epigenetic-modifying agents have created new opportunities for epigenetic therapies for patients with this complex group of diseases.Areas covered: The present review summarizes current knowledge on epigenetic alterations in T-cell lymphomas, availability, and mechanisms of action of epigenetic-modifying agents, results of clinical trials of epigenetic therapies in T-cell lymphomas, status of FDA approval, and biomarker approaches to guide therapy. Promising future directions are discussed.Expert opinion: Mutations in epigenetic-modifying genes are among the most common genetic alterations in T-cell lymphomas, highlighting the potential for epigenetic therapies to improve management of this group of diseases. Single-agent efficacy is well documented, leading to FDA approval for several indications, but overall response rates and durability of responses remain modest. Critical next steps for the field include optimizing combination therapies that incorporate epigenetic-modifying agents and developing predictive biomarkers that help guide patient and drug selection.


    Nada Ahmed, Andrew L Feldman. Targeting epigenetic regulators in the treatment of T-cell lymphoma. Expert review of hematology. 2020 Feb;13(2):127-139

    Expand section icon Mesh Tags

    Expand section icon Substances

    PMID: 31903826

    View Full Text